The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.
Daniel Alexander is a QC at 8 New Square. With over 20 years' experience of litigation and advice in intellectual property cases, his practice covers all areas of intellectual property. Cases have involved medical and plant biotechnology (including SPCs), pharmaceuticals, chemical process design, telecommunications and mobile phones.
Charlotte May is a barrister at 8 New Square. She was appointed as Standing Counsel to the Comptroller General of Patents and Trade Marks in December 2008, and has wide ranging experience in SPC related disputes in both the UK courts and the ECJ including Generics v Synaptech and Astellas Pharma Incv Comptroller-General of Patents.
Sebastian Moore is a Partner in Intellectual Property at Herbert Smith. As well as running large multi-jurisdictional pharmaceutical patent actions (including the first streamlined patent action to come to trial), he has advised a number of pharmaceutical and biotechnology companies on licensing and freedom to operate issues. He is a guest lecturer at the University of London and a tutor on the Oxford University Diploma in Intellectual Property Law and Practice.
Jonathan Turnbull is an Associate in Herbert Smith's Intellectual Property Team
Gordon Wright is a Partner at Elkington and Fife LLP. Having worked over 20 years in the pharmaceutical industry, most recently as Head of Intellectual Property for Sanofi- Synthelabo in France, Gordon Wright handles mainly chemical and pharmaceutical subject matter. Gordon has an in-depth knowledge of IP topics specifically related to the pharmaceutical industry, including in particular supplementary protection certificates (SPCs), regulatory data exclusivity, product life cycle management, pharmaceutical trade marks, parallel imports and arrangements, often taking a key part in structuring the deal and drafting the agreements.